上海奥浦迈生物科技股份有限公司 第二届监事会第十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688293 证券简称：奥浦迈 公告编号：2025-061 一、监事会会议召开情况 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）第二 届监事会第十次会议于2025年8月21日通过现场表决与通讯相结合的方式召开。 本次会议通知及相关资料已于2025年8月11日送达全体监事。本次会议由监事会 主席梁欠欠女士召集并主持，会议应出席监事3名，实际出席监事3名，本次会议 的召集、召开方式符合相关法律、行政法规、部门规章、规范性文件和《公司章 程》的规定，会议决议合法有效。 专项报告>的议案》 监事会认为：公司2025年半年度募集资金存放与实际使用情况符合《上海证 券交易所科创板股票上市规则》《上市公司募集资金监管规则》《上海奥浦迈生 物科技股份有限公司募集资金管理办法》等相关法律法规和公司制度的规定，公 司募集资金使用专户存储和专项使用，并及时履行了相关信息披露义务，募集资 金的使用审议程序合法 ...

Key Points - The report details the fundraising and usage of funds by Shanghai Aopumai Biotechnology Co., Ltd. for the first half of 2025, ensuring compliance with relevant regulations [1][2] - The total amount raised from the initial public offering (IPO) was approximately RMB 1.644 billion, with a net amount of RMB 1.637 billion after deducting issuance costs [1] - As of June 30, 2025, the company had spent RMB 318.4048 million on fundraising projects and had a remaining balance of RMB 151.2954 million in the fundraising account [1][2] Fundraising Overview - The actual amount raised was RMB 1,643,705,576.40, with a net amount of RMB 1,637,000,000 after fees [1] - The company utilized RMB 318.4048 million for project expenditures and invested RMB 546 million in financial products [1] - The company generated a net interest income of RMB 48.6477 million from the funds [1] Fund Usage and Management - The company has established a dedicated account for fundraising, with a balance of RMB 151.2954 million as of June 30, 2025 [1][2] - The company has permanently supplemented working capital with surplus funds amounting to RMB 192.8819 million [1] - The company has implemented a cash management strategy for idle funds, allowing for investment in high-security, liquid financial products [2][3] Project Status - The company has completed the fundraising projects "Aopumai CDMO Biopharmaceutical Commercialization Production Platform" and "Aopumai Cell Culture R&D Center," with surplus funds permanently allocated to working capital [1][2] - There were no changes to the fundraising project usage during the reporting period [4] Compliance and Reporting - The company has adhered to the regulations regarding fundraising management and disclosure, ensuring timely and accurate reporting of fundraising activities [4] - There were no violations in the management and disclosure of fundraising [4]

Group 1 - The company will hold a half-year performance briefing on September 3, 2025, from 13:00 to 14:00 [1][2] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [2][3] - Key personnel attending the briefing include the Chairman, General Manager, CFO, independent directors, and the Secretary of the Board [2] Group 2 - Investors can submit questions for the briefing from August 27, 2025, to September 2, 2025, before 16:00 [3] - The company encourages participation through the Shanghai Stock Exchange Roadshow Center website [3] - After the briefing, investors can access the main content and details of the event on the same website [3]

Core Viewpoint - The company is committed to enhancing its core business and competitiveness through increased R&D investment and operational efficiency, while also focusing on investor returns and sustainable growth [1][5][6] Group 1: Business Focus and R&D Investment - The company specializes in cell culture products and services, aiming to provide comprehensive solutions for the biopharmaceutical industry [1] - R&D investment has consistently exceeded 10% of annual revenue, with a focus on developing proprietary technologies and expanding product lines [11][10] - The company has developed multiple new cell culture media products, enhancing its competitive edge in therapeutic protein production [12][13] Group 2: Financial Performance and Market Expansion - The sales revenue from cell culture products increased by 25.49% year-on-year, driven by the steady progress of client pipelines and rapid overseas expansion [2] - The company served over 700 domestic and international biopharmaceutical enterprises and research institutions, solidifying its market position [2][10] - The CDMO service business also showed positive growth, with a revenue increase of 13.24% compared to the previous year [2] Group 3: Investor Relations and Return Mechanisms - The company maintains a stable cash dividend policy, distributing a total of 22,709,750.80 yuan in cash dividends for the 2025 mid-year [5][6] - A share repurchase plan was completed, with a total transaction amount of 50,998,163.75 yuan, aimed at enhancing long-term investment value [7][8] - The company plans to implement a mid-year profit distribution of 2.30 yuan per share, amounting to 26,116,213.42 yuan, which represents 69.56% of the net profit for the first half of 2025 [6] Group 4: Internal Management and Quality Control - The company has successfully passed ISO9001:2015 quality management system audits, demonstrating its commitment to high-quality standards [16] - Continuous improvement in internal control systems and governance structures is prioritized to enhance operational efficiency and risk management [19][20] - The company emphasizes talent development, with over 70% of R&D personnel holding master's or doctoral degrees, fostering a strong innovation culture [17][18] Group 5: Future Outlook and Strategic Initiatives - The company is actively pursuing a major asset restructuring to enhance operational quality and risk resilience [17][18] - Plans to explore various share repurchase methods to strengthen capital structure and enhance investor value are in place [8] - The company aims to expand its international market presence while continuously optimizing product offerings and service quality [15][16]

Summary of Key Points Core Viewpoint - The company, Shanghai Aopumai Biotechnology Co., Ltd., plans to utilize part of its idle raised funds for cash management, with a maximum investment amount of RMB 700 million, ensuring high safety and liquidity in the investment products chosen [1][2][8]. Investment Overview - **Investment Purpose**: The aim is to maximize shareholder value by improving the efficiency of fund usage while ensuring that the use of raised funds is not affected and risks are effectively controlled [2][6]. - **Investment Amount and Duration**: The company intends to use up to RMB 700 million for cash management, with the funds being able to roll over within a 12-month period [2][5]. - **Source of Funds**: The funds are sourced from the proceeds of the company's initial public offering, which raised a total of approximately RMB 1.64 billion after deducting issuance costs [2][5]. Investment Methodology - The company will invest in high-safety, liquid financial products such as agreement deposits, structured deposits, time deposits, notice deposits, large certificates of deposit, and income certificates [1][5][6]. - The cash management products will not be used for pledging or for investment purposes in securities [5][6]. Approval Process - The board of directors and the supervisory board approved the cash management proposal during meetings held on August 21, 2025, with a validity period of 12 months from the date of approval [2][6][8]. - The management team has been authorized to make investment decisions and sign relevant contracts, with the finance department responsible for implementation [1][6]. Opinions from Supervisory Board and Sponsor - The supervisory board supports the cash management initiative, stating it will not affect the use of raised funds or harm the interests of the company and its shareholders [7][8]. - The sponsor, Guotai Junan Securities, has confirmed that the cash management plan complies with relevant regulations and will enhance fund usage efficiency without altering the intended use of raised funds [8].

Core Viewpoint - The company has approved the formulation and revision of certain governance systems to enhance operational standards and protect shareholder rights [1][2]. Group 1: Governance System Revisions - The board of directors convened on August 21, 2025, to review and approve the proposal for governance system revisions [1]. - The revisions are in accordance with various laws and regulations, including the Company Law and Securities Law of the People's Republic of China [1]. - The specific governance systems being established and revised include the "Market Value Management System" and the "Public Opinion Management System" [1]. Group 2: Market Value Management System - The "Market Value Management System" consists of five chapters and seventeen articles, covering basic principles, management structure, main methods, monitoring mechanisms, and emergency measures [2]. - The aim of this system is to enhance the company's market value management practices and improve investor returns [1][2]. Group 3: Public Opinion Management System - The "Public Opinion Management System" includes four chapters and sixteen articles, focusing on the organizational structure and responsibilities for managing public opinion, as well as principles and measures for handling various types of public opinion information [2]. - This system is designed to strengthen the company's ability to respond to public sentiment and establish a rapid response and emergency handling mechanism [1][2].

证券代码：688293 证券简称：奥浦迈 公告编号：2025-068 上海奥浦迈生物科技股份有限公司 关于 2025 年半年度计提资产减值准备的公告 （二）资产减值损失——存货跌价损失 根据《上海证券交易所科创板股票上市规则》《企业会计准则》等相关法律 法规的规定，为真实、准确、公允的反映上海奥浦迈生物科技股份有限公司（以 下简称"奥浦迈"或"公司"）2025年半年度的财务状况及经营情况，基于谨慎性原 则，公司对合并报表范围内截至2025年6月30日的各类资产进行减值测试，对存 在减值迹象的有关资产计提了减值准备。现将相关情况公告如下： 一、计提资产减值准备的情况概述 公司2025年半年度拟计提信用减值损失和资产减值损失共计639.11万元，具 体情况如下表： | | | 单位：万元 | 币种：人民币 | | | --- | --- | --- | --- | --- | | | 项目 | 2025 | 年半年度预计计提金额 | | | 信用减值损失 | | 应收账款坏账损失 | | 430.61 | | 资产减值损失 | | 存货跌价损失 | | 208.50 | | | 合计 | | 639.11 | | ...

Core Viewpoint - The document outlines the management system for the temporary suspension and exemption of information disclosure by Shanghai Aopumai Biotechnology Co., Ltd, ensuring compliance with relevant laws and regulations [1][2]. Group 1: General Provisions - The purpose of the system is to regulate the handling of temporary suspension and exemption of information disclosure, urging the company and related parties to fulfill their disclosure obligations in accordance with the law [1]. - The system applies to the handling of temporary suspension and exemption of information disclosure as per the Securities Law, the listing rules of the Science and Technology Innovation Board, and other relevant regulations [1][2]. Group 2: Scope of Temporary Suspension and Exemption - Information that involves trade secrets or confidential business information may be temporarily suspended or exempted from disclosure if it meets certain conditions, such as potential harm to the company or others' interests [2][3]. - If there is sufficient evidence that the information involves state secrets, it may be exempted from disclosure in accordance with the law [2][3]. Group 3: Procedures for Temporary Suspension and Exemption - The company’s board secretary is responsible for organizing and coordinating matters related to the temporary suspension and exemption of information disclosure [4]. - Relevant departments must submit written materials regarding the reasons for suspension or exemption, ensuring the accuracy and completeness of the information [4][5]. Group 4: Internal Review Process - The internal review process for temporary suspension or exemption involves submitting applications to the securities affairs department, which are then reviewed by the board secretary and approved by the chairman [6]. - If the application for suspension or exemption is not approved, the company must disclose the information in accordance with regulatory requirements [6]. Group 5: Accountability and Penalties - The company has established a mechanism for accountability regarding the temporary suspension and exemption of information disclosure, with potential penalties for those responsible for non-compliance [7]. - The company reserves the right to pursue responsibility against consultants or intermediaries who disclose company information without authorization, leading to losses [7]. Group 6: Miscellaneous Provisions - Other matters related to the temporary suspension and exemption of information disclosure must comply with the relevant rules and regulations of the Science and Technology Innovation Board and other applicable laws [9]. - The system will take effect upon approval by the company's board of directors and will be revised as necessary [9].

Summary of Key Points Core Viewpoint The company intends to utilize part of its temporarily idle raised funds for cash management to enhance fund efficiency and maximize shareholder returns while ensuring compliance with regulations and maintaining the intended use of the raised funds [1][7]. Group 1: Fundraising and Management - The company raised a total of RMB 1,643,705,576.40 through its initial public offering, with a net amount after expenses being RMB 1,643,705,576.40 [1][2]. - All raised funds are managed in a dedicated account, with agreements in place between the company, its subsidiaries, and the commercial banks [2]. Group 2: Cash Management Plan - The company plans to use up to RMB 70,000.00 million of temporarily idle raised funds for cash management, with a rolling usage period of 12 months [3][4]. - The investment products will include safe and liquid options such as fixed deposits and structured deposits, ensuring that these funds are not used for pledging or securities investment [4]. Group 3: Approval and Oversight - The board of directors and the supervisory board have approved the cash management plan, confirming that it will not affect the normal operation of the fundraising projects [5][6]. - The supervisory board supports the plan, stating it will not harm the interests of the company or its shareholders [6]. Group 4: Compliance and Risk Management - The cash management activities are in compliance with relevant regulations and internal management systems, ensuring no change in the intended use of the raised funds [7]. - The company will implement strict risk control measures, focusing on high-security and high-liquidity investment products, while monitoring market conditions [5].

证券代码：688293 证券简称：奥浦迈 公告编号：2025-070 上海奥浦迈生物科技股份有限公司 首次公开发行部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 本次股票上市流通总数为36,139,446股。 ? 本次股票上市流通日期为2025 年 9 月 2 日。 一、 本次上市流通的限售股类型 年转让的公司的股份不超过本人持有的公司股份总数的百分之二十五，任期届满 离职后半年内不得转让公司股份。如本人在任期届满前离职的，在本人就任时确 定的任期内和任期届满后六个月内不得转让持有的公司股份。如上述三十六个月 锁定期满，则每年转让的公司的股份不超过本人持有的公司股份总数的百分之二 十五，但自离职之日起六个月内不转让本人持有的公司股份。上述三十六个月锁 定期满且本人在公司担任核心技术人员期间，每年转让的公司的股份不超过本人 持有的公司股份总数的百分之二十五，离职后半年内不得转让持有的公司股份。 现金红利、送股、转增股本 ...